ACB $1.430 (1.42%)

ACNNF $0.030 (0%)

AERO $3.210 (0%)

ALEAF $0.050 (-14.97%)

AMMJ $0.048 (12.81%)

APHA $15.380 (0%)

ARNA $99.990 (0%)

ATT:CNX $0.080 (0%)

AUSA:CNX $0.065 (0%)

AUSAF $0.050 (0%)

AVXL $11.060 (-0.98%)

BAMM:CNX $0.130 (0%)

BBM:CNX $0.030 (-14.29%)

BBRRF $0.027 (-3.27%)

BE:CNX $0.005 (0%)

BIO:CNX $0.013 (0%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.395 (2.6%)

BLOZF $0.308 (2.5%)

BUDZ $0.100 (-9.09%)

CADMF $0.052 (0%)

CALI:CNX $0.085 (13.33%)

CANN $0.230 (-2.13%)

CARA $9.060 (-6.69%)

CBWTF $0.062 (0.16%)

CGC $2.540 (-0.97%)

CGRW $0.016 (-22%)

CHOO:CNX $0.005 (0%)

CHOOF $0.003 (-16%)

CNBX $3.990 (0%)

CNGGF $0.203 (0%)

CODI $22.680 (0.22%)

CPMD $0.020 (-4.81%)

CRBP $0.281 (0.07%)

CRON $3.050 (0.33%)

CROP:CNX $0.015 (0%)

CSI:CNX $0.070 (-12.5%)

CURR $0.349 (2.65%)

CVSI $0.033 (7.49%)

DIGP $0.014 (0%)

EEVVF $0.078 (0%)

EMHTF $0.039 (10.17%)

EPWCF $0.059 (0%)

FFT:CNX $0.040 (0%)

FNNZF $0.075 (13.64%)

GNBT $0.001 (0%)

GRIN:CNX $0.075 (-16.67%)

GRWG $4.840 (-1.83%)

GTBIF $10.150 (-1.46%)

GTII:CNX $13.090 (-1.65%)

GWPH $218.960 (0%)

HEXO $0.196 (-0.56%)

HHPHF $0.079 (0%)

HLSPY $0.363 (0%)

HMLSF $2.800 (0%)

HMPPF $0.498 (0%)

HRVOF $0.023 (-11.07%)

HSTRF $0.135 (0%)

HUGE:CNX $1.180 (-1.67%)

IAN:CNX $0.075 (0%)

IGC $0.520 (-3.02%)

IGXT $0.219 (13.76%)

IIPR $92.910 (-2.5%)

INQD $0.009 (-3.23%)

IONC:CNX $0.005 (0%)

IONKF $0.005 (-2.04%)

ISOL:CNX $0.035 (0%)

ITHUF $0.062 (5.65%)

KBEV:CNX $0.045 (0%)

KHRNF $0.091 (-2.15%)

KSHB $0.695 (0%)

LHS:CNX $1.470 (0%)

LHSIF $1.145 (0%)

LXX:CNX $8.400 (0%)

MCIG $0.028 (0%)

MEDIF $0.057 (1.15%)

MGWFF $0.060 (9.57%)

MJ:CNX $0.050 (0%)

MJNA $0.015 (1.4%)

MNTR $0.040 (0%)

MYM:CNX $0.140 (0%)

MYMMF $0.106 (0%)

NCNNF $0.058 (0%)

NDVAF $0.111 (-6.17%)

NGW:CNX $0.410 (0%)

NRXCF $0.035 (0%)

NSPDF $0.010 (-23.53%)

NVTQF $0.596 (0%)

NWKRF $0.424 (0%)

NXGWF $0.316 (0%)

NXTTF $0.033 (6.61%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

PHCG $0.001 (0%)

PHVAF $0.038 (0%)

PILL:CNX $0.230 (-17.86%)

PKG:CNX $0.020 (-20%)

PLPRF $0.357 (0%)

PLUS:CNX $0.440 (0%)

PMCB $2.420 (0%)

PNPL $0.012 (0%)

PTNYF $0.018 (3.24%)

QCA:CNX $0.095 (-5%)

RDDTF $0.020 (1.53%)

RLLVF $0.001 (0%)

RMHB $0.028 (2.8%)

RQB:CNX $0.005 (0%)

RQHTF $0.448 (2.99%)

SLNG:CNX $0.095 (-9.52%)

SMG $83.180 (-1.21%)

SNN:CNX $0.155 (0%)

SOL:CNX $0.320 (0%)

SOLCF $0.250 (0%)

SPLIF $0.016 (-15.79%)

SPRWF $0.268 (0%)

STEM:CNX $0.035 (0%)

STMH $0.028 (1.45%)

SUN:CNX $0.150 (0%)

TBPMF $0.052 (3.82%)

TCAN:CNX $0.135 (0%)

TCNAF $0.080 (0%)

TER:CNX $3.480 (-0.57%)

TGEN $1.200 (0%)

TGIF:CNX $0.025 (-16.67%)

TGIFF $0.020 (-12.28%)

THC:CNX $0.048 (0%)

THCBF $0.044 (12.85%)

TLRY $3.540 (1.14%)

TRLFF $0.035 (0%)

TRSSF $2.710 (0.37%)

TURV $0.001 (0%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.015 (0%)

VPRB $0.047 (-6%)

VRTHF $0.026 (0%)

VVCIF $0.035 (-8.14%)

WAYL:CNX $0.740 (0%)

XXII $1.740 (-12.12%)

ZDPY $0.740 (-2.63%)

ZYNE $1.190 (-0.83%)

Back

SNDL Reports Second Quarter 2023 Financial and Operational Results

Aug 14, 2023 • 10:00 AM EDT
21 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

CALGARY, AB, Aug. 14, 2023 /PRNewswire/ – SNDL Inc. (NASDAQ: SNDL) (“SNDL” or the “Company“) reported its financial and operational results for the second quarter ended June 30, 2023. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

SNDL has also posted a supplemental investor presentation on its website, which can be found at https://sndl.com.

SECOND QUARTER 2023 FINANCIAL AND OPERATIONAL HIGHLIGHTS

  • Net revenue for the second quarter of 2023 of $244.5 million, compared to $223.7 million in the corresponding period of 2022, an increase of 9.3%. This marks an all-time high for the Company, underscoring SNDL’s strategic initiatives and operational enhancements, which have led to financial and operational improvements.
    • Liquor Retail: Net revenue of $151.7 million for the second quarter of 2023, an increase of 2.1% compared to the prior year.
    • Cannabis Retail: Net revenue of $71.9 million for the second quarter of 2023, an increase of 13.2% compared to the prior year.
    • Cannabis Operations: Net revenue of $20.9 million for the second quarter of 2023, an increase of 81% compared to the prior year.
  • Record gross margin of $51.9 million in the second quarter of 2023, compared to $43.1 million in the second quarter of 2022. The 21% increase in gross margin year-over-year is driven by cost-saving measures, supply chain efficiencies, improved pricing strategies, economies of scale, and product mix optimization.
  • Net loss of $33.2 million for the second quarter of 2023, compared to a $74.0 million net loss in the second quarter of 2022. The loss was driven by one-time events, including the Valens Company (“Valens“) integration and related costs, as well as by realized losses from equity investments.
  • Adjusted EBITDA of $2.2 million for the second quarter of 2023, compared to a loss of $25.9 million from the second quarter of 2022, reflecting the improvement in the financial performance of SNDL’s operating segments along with synergies realized through the Company’s vertical integration strategies.
  • During the second quarter of 2023, a total of $8.8 million cash was used in operating activities, compared to $17.9 million in the same quarter of last year, an improvement of 51%, showcasing the Company’s enhanced operational efficiency.
  • SNDL currently has five credit exposures in the SunStream portfolio following the monetization of a credit exposure in July 2023. The current portfolio includes one credit under a court-supervised receivership process and another in active restructuring negotiations.
  • $754 million of unrestricted cash, marketable securities and investments, and no outstanding debt at June 30, 2023, resulting in a net book value per share of $4.86; and $182.6 million of unrestricted cash at August 11, 2023. SNDL has not raised cash through share offerings since June 2021.

“Our incredible two-year journey from less than $10 million of net revenue and negative gross margin in Q2 2021 to our current trajectory of reaching an expected $1 billion in annual revenue and continued gross margin growth in 2023 is a testament to our team’s commitment to becoming a leader in Canadian regulated products,” said Zach George, Chief Executive Officer of SNDL. “We have taken decisive steps to simplify operations throughout our business segments with a sharp focus on the goal of reaching profitability in 2024. In Liquor Retail, we are capitalizing on margin accretive product opportunities and modest expansion. In Cannabis Retail, our data licensing program is driving improved profitability and supplier relationships, and we look to enhance consumer engagement through new loyalty capabilities. In our Cannabis Operations, we have taken aggressive cost-cutting measures, streamlined manufacturing operations, and reduced reliance on high-cost cultivation. During this process, we have maintained cannabis sales momentum and are actively exploring B2B and international opportunities. We have also simplified our investment portfolio by divesting from securities, prioritizing the opportunity to return capital to our shareholders.”

“Over the last two years, SNDL has grown both organically and by acquisition while our leaders have implemented bold changes throughout the business,” added George. “We believe that we now have the requisite scale and platform optionality to create sustainable shareholder value. We expect our Canadian retail network to continue to grow at a modest pace while our internal focus on optimization is in the early stages of producing tangible results. We look forward to updating investors on the closing of the Nova transaction, and events related to our SunStream portfolio as we focus on delivering improved performance in the second half of 2023.”

SECOND QUARTER 2023 KEY FINANCIAL METRICS

OPERATING SEGMENTS

($000s)

Liquor
Retail

Cannabis
Retail

Cannabis
Operations

Investments

Corporate

Total

Three months ended June 30, 2023

Net revenue

151,690

71,881

20,940

244,511

Gross margin

35,360

17,780

(1,207)

51,933

Earnings (loss) from Operations

8,207

2,340

(14,134)

(1,660)

(24,242)

(29,489)

Three months ended June 30, 2022

Net revenue

148,637

63,494

11,564

223,695

Gross margin

33,528

13,897

(4,346)

43,079

Earnings (loss) from Operations

11,288

1,476

(8,293)

(69,973)

(15,914)

(81,416)

SECOND QUARTER 2023 RESULTS

SNDL’s business is operated and reported in four segments: Liquor Retail, Cannabis Retail, Cannabis Operations and Investments.

Liquor Retail

SNDL is Canada’s largest private sector liquor retailer, operating 170 locations, predominantly in Alberta, under its three retail banners: “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”.

  • Net revenue for Liquor Retail sales for the three banners combined was $151.7 million for the second quarter of 2023, an increase of 2.1% compared to the second quarter of 2022.
  • Same stores sales increased 1.7% across all liquor banners, with Liquor Depot and Ace Liquor seeing 5.6% and 2.8% in same-store sale increases, respectively.
  • Gross margin in the Liquor Retail segment was $35.4 million, or 23.3% of sales in the second quarter of 2023, compared to $33.5 million, or 22.6% of sales, in the second quarter of 2022. The 5.5% gross margin growth is mainly driven by procurement productivity and product mix management initiatives.
  • Preferred label sales, which are a substantial driver of gross margin growth, increased 28% compared to the second quarter of 2022 and 22% compared to the first quarter of 2023.
  • SNDL’s liquor banners’ market share in Alberta was approximately 18% in the second quarter of 2023, with Wine and Beyond representing approximately 3% from only 11 stores in the province, showcasing the continued success of the banner. Sales at the Wine and Beyond in Kelowna, British Columbia, continue to increase year-over-year, further validating the banner’s expansion strategy into Saskatchewan in 2024.
  • SNDL expects to launch an e-commerce platform for its Liquor Retail banner, Wine and Beyond, which presents significant opportunities to drive accretive revenues. It is expected to provide the Company with a scalable and adaptable platform to expand its market presence, increase customer engagement, and capitalize on the growing trend of online shopping for liquor products. The launch date is scheduled for the third quarter of 2023.
  • As of August 11, 2023, the Ace Liquor store count is 138, the Liquor Depot store count is 20, and the Wine and Beyond store count is 12.

Cannabis Retail

With its ownership interest in Nova, SNDL is Canada’s largest private-sector cannabis retailer, operating 196 locations under its four retail banners: Value Buds, Spiritleaf, Superette, and Firesale Cannabis. SNDL’s Cannabis Retail strategy is based on several factors, including the quality of its store locations, the range of products it offers, and the unique experiences it provides customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

On July 25, 2023, SNDL and Nova announced that while all other provincial approvals have been received, the continued review by one provincial regulator has necessitated the extension of the outside date for the closing of the previously-announced strategic partnership (the “Transaction“). SNDL and Nova anticipate that the Transaction will close on or before August 25, 2023, subject to the receipt of regulatory approval and the amendment to certain terms of the Transaction that are mutually satisfactory to SNDL and Nova.

  • Net revenue from the Cannabis Retail segment for the second quarter of 2023 was $71.9 million, compared to $63.5 million in the second quarter of 2022, a 13.2% increase year-over-year and a record for the segment since SNDL diversified into Cannabis Retail.
  • Same stores sales for the second quarter of 2023 increased 3.3% across all Cannabis Retail banners, compared to the same period in the year prior. Nova’s same store sales increased 38% for the period.
  • Gross margin of $17.8 million, or 24.7% of sales, up by close to 28% compared to the second quarter of 2022, showcasing the Company’s efforts in continued margin expansion initiatives.
  • In the first half of 2023, SNDL took proactive steps to optimize its proprietary data licensing program for the Cannabis Retail segment, aiming to create mutually beneficial results for its retail operations and licensed producer partners. This margin accretive opportunity has resulted in revenue for the second quarter of 2023 of $2.7 million, compared to $1.3 million in the second quarter of 2022, and represents growth of 80% compared to the first quarter of 2023. By leveraging the volume of Nova’s retail locations and the Company’s access to high-quality analytics, it expects to deliver continued successful outcomes for its partners and drive top-line revenue and margin growth.
  • The Company partnered with Nova for Value Buds’ private label products, and sales of Value Buds products represented approximately 6.6% of total 28-gram sales and 18.0% of 14-gram sales in Value Buds locations nationwide.
  • As of August 11, 2023, the Spiritleaf store count is 98 (21 corporate stores and 77 franchise stores), the Value Buds store count is 91 corporate stores, the Superette store count is five corporate stores, and the Firesale store count is two corporate stores.

Cannabis Operations

SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities, premium cultivation and manufacturing facilities, the Cannabis Operations segment is a key enabler of SNDL’s vertical integration strategy.

  • Net revenue from the Cannabis Operations segment for the second quarter of 2023 was $20.9 million, an 81% increase compared to the second quarter of 2022, and a 9% increase compared to the first quarter of 2023.
  • Gross margin of negative $1.2 million in the second quarter of 2023, compared to negative $4.3 million in the second quarter of 2022, and negative $9.5 million in the first quarter of 2023. The improved results showcase the Company’s focus on bolstering margins through increased product distribution and streamlining the Cannabis Operations segment.
  • In the first half of 2023, SNDL implemented aggressive cost-cutting measures and improved manufacturing efficiency. A key initiative involved right-sizing cannabis cultivation in Olds, Alberta to focus on producing premium products.
  • Subsequently, SNDL successfully centralized most manufacturing activities and consolidated processing, labelling, and excising at its Kelowna facilities. This move optimizes resource allocation and streamlines operations to significantly reduce costs.
  • Following the Valens acquisition, the Company underwent a meticulous evaluation of its portfolio, focusing on higher-margin brands and products. SNDL’s vertical integration capabilities facilitate informed and data-driven product portfolio decisions. This strategic alignment enables SNDL to effectively enhance overall market positioning and product offerings.
  • Market share in owned retail continues to scale through the Company’s vertical integration strategy. Driving increased owned retail share is a key focus for the Company and a meaningful contributor to overall margin and profit growth. As a supplement to this strategy, SNDL partnered with ColdHaus Direct (“ColdHaus“) in May of 2023 to manage the Company’s in-market sales and logistics execution for its branded cannabis products.

Investments

  • As of the end of the second quarter of 2023, the Company had deployed capital on a portfolio of cannabis-related investments with a carrying value of $569.0 million, including $532.8 million through the SunStream Bancorp Inc. joint venture (“SunStream“).
  • For the second quarter of 2023, the investment portfolio generated a net loss of $1.5 million, mainly driven by interest and fee revenue of $3.2 million, and an investment loss of $3.8 million on marketable securities. To streamline its business operations, SunStream made the strategic decision to divest certain cannabis investments, and as part of this process, the Company realized losses. The realized loss on marketable securities and the reversal of the unrealized loss on marketable securities was due to the disposition of shares in cannabis-related investments.
  • At the end of the second quarter of 2023, SunStream’s credit portfolio comprised six investments: Jushi Holdings, SKYMINT Brands (“Skymint“), Ascend Wellness Holdings, Parallel Inc. (“Parallel“), Columbia Care Inc., and AFC Gamma, Inc. The AFC Gamma, Inc. investment was monetized above carrying value subsequent to the end of the second quarter of 2023.
  • SunStream is actively implementing a stock-exchange compliant structure to facilitate participation in US cannabis companies. In connection, SunStream is exploring the restructuring and transfer of certain credit interests in Skymint and Parallel to a new US holding entity (“Sunstream USA“). The SunStream USA structure is expected to allow SNDL to participate in SunStream assets while complying with all US federal and state laws. This SunStream USA structure is anticipated to include the issuance of securities upon the equitization of specific credit instruments held by SunStream. In turn, SNDL would hold non-voting shares in SunStream USA, with the right to exchange such shares into common shares in the future, if certain conditions are met. As such, the Sunstream USA structure is expected to allow SNDL to participate in SunStream assets through a revamped capital structure. The proposed Sunstream USA structure will be reviewed by Nasdaq, as the relevant listing authority for SNDL, prior to its execution. SNDL anticipates providing further details on progress with the Skymint and Parallel restructuring initiatives in the third quarter of 2023.

Three months ended
June 30

Six months ended
June 30

($000s)

2023

2022

2023

2022

Interest and fee revenue

Interest revenue from investments at amortized cost

922

818

1,928

1,813

Interest and fee revenue from investments at Fair
Value Through Profit or Loss

250

543

874

2,659

Interest revenue from cash

2,014

1,216

4,595

1,966

 Total interest and fee revenue

3,186

2,577

7,397

6,438

Investment revenue (loss)

Realized (losses) gains

(48,988)

265

(92,792)

389

Unrealized gains (losses)

45,182

(35,338)

84,100

(53,172)

 Total investment revenue/(loss)

(3,806)

(35,073)

(8,692)

(52,783)

Share of profit (loss) of equity-accounted investees

(936)

(37,978)

8,580

(33,887)

Total investment activities

(1,556)

(70,474)

7,285

(80,232)

Liquidity Position

  • As at June 30, 2023, and August 11, 2023, the Company had unrestricted cash balances of $185.5 million and $182.6 million, respectively, and a total of approximately 260 million shares outstanding as at August 11, 2023.
  • The Company’s share repurchase program continues to be available to lower the outstanding share float and increase the earnings per share for shareholders. SNDL will continue to assess opportunities to utilize the program to the extent that management believes SNDL’s shares are undervalued. For the three months ended June 30, 2023, the Company did not purchase or cancel common shares.

STRATEGIC AND ORGANIZATIONAL UPDATE

SNDL remains focused on building long-term shareholder value through vertical integration, the accretive deployment of cash resources, expansion of its retail distribution network, the further streamlining of the Company’s operating structure, and enhanced offerings of high-quality brands within the Liquor Retail, Cannabis Retail and Cannabis Operations segments.

Integration Initiatives

The Company has achieved $18.2 million in annualized cost savings since the Valens acquisition in January 2023. These initiatives surpass the Company’s original $10 million cost savings target. Most of the cost savings have been realized through SG&A, public company costs, as well as supply chain consolidation and operational efficiency. By 2024, run-rate synergies are expected to exceed $30 million annually, and proceeds from asset sales are expected to total $9 million.

The integration work has allowed the Company to undertake a comprehensive organizational design update, restructuring certain departments to achieve scale, support growth, and reinforce key initiatives. The organizational design work supports a more efficient structuring of SNDL’s shared service teams to realize additional cost savings and enable targeted focus on key initiatives, such as loyalty, e-commerce, increasing market share within owned retail, and manufacturing, cultivation and processing improvements.

The Company’s integration initiatives are critical to SNDL’s vision of establishing Canada’s largest regulated products platform and generating sustainable free cash flow.

SNDL’s strategy is predicated on the below key objectives:

  • Generate positive cash flow from all operating segments by 2024.
  • Maximize the profitability and sustainability of SNDL’s Liquor Retail segment.
  • Establish a dominant multi-banner cannabis retail platform with a national presence.
  • Streamline SNDL’s cannabis production and drive profitable market share.

This press release is intended to be read in conjunction with the Company’s Financial Statements and Notes for the period ended June 30, 2023, and the accompanying Management’s Discussion and Analysis (“MD&A“). These reports are available under the Company’s profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

CONFERENCE CALL

The Company will hold a conference call and webcast at 10:30 a.m. EST (8:30 a.m. MST) on Monday, August 14, 2023.

WEBCAST ACCESS

To access the live webcast of the call, please visit the following link:
https://services.choruscall.ca/links/sndl2023q2.html

REPLAY

A telephone replay will be available for one month. To access the replay, dial:
Canada/USA Toll Free: 1-800-319-6413 or International Toll: +1-604-638-9010
When prompted, enter Replay Access Code: 0323#
The webcast archive will be available for three months via the link provided above.

ABOUT SNDL INC. 

SNDL is a public company whose shares are traded on the Nasdaq under the symbol “SNDL.”

SNDL is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. SNDL is a licensed cannabis producer and one of the largest vertically integrated cannabis companies in Canada specializing in low-cost biomass sourcing, premium indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Citizen Stash, Sundial Cannabis, Palmetto, Bon Jak, Spiritleaf Selects, Versus Cannabis, Value Buds, Vacay, Grasslands and Superette. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information on SNDL, please go to https://sndl.com/.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements“), including, but not limited to, statements regarding the Company’s operational goals, demand for the Company’s products, the Company’s ability to achieve profitability or its goal of sustainable, positive gross margin and positive free cash flow, the development of the legal cannabis industry, performance of the Company’s investments, including through the SunStream joint venture, any potential forms of shareholder value creation, the ability to realize expected cost savings and the expansion of product offerings, brand and market share and retail networks, and the closing, integration and realization of expected benefits of, as applicable, the acquisition of The Valens Company, Zenabis and Superette. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, ”likely”, “outlook”, “forecast”, ”may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see “Item 3.D.—Risk Factors” in the Company’s annual report on Form 20-F, filed with the Securities and Exchange Commission (“SEC“) on April 24, 2023, and the risk factors included in our other SEC filings for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Unaudited – expressed in thousands of Canadian dollars, except per share amounts)

Three months ended
June 30

Six months ended
June 30

2023

2022

2023

2022

Gross revenue

257,425

227,557

470,324

247,684

Excise taxes

12,914

3,862

23,361

6,392

Net revenue

244,511

223,695

446,963

241,292

Cost of sales

188,922

174,291

347,071

188,617

Inventory impairment and obsolescence

4,291

3,871

13,468

5,852

Gross margin before fair value adjustments

51,298

45,533

86,424

46,823

Change in fair value of biological assets

(1,413)

(388)

(4,948)

3,302

Change in fair value realized through inventory

2,048

(2,066)

2,998

(3,627)

Gross margin

51,933

43,079

84,474

46,498

Interest and fee revenue

3,421

2,577

7,632

6,438

Investment loss

(4,020)

(35,073)

(9,189)

(52,783)

Share of profit (loss) of equity-accounted investees

(936)

(37,978)

8,580

(33,887)

General and administrative

52,727

40,293

101,300

50,975

Sales and marketing

4,104

3,132

7,490

4,243

Research and development

20

390

160

485

Depreciation and amortization

13,443

8,800

29,911

9,539

Share-based compensation

3,893

438

6,102

4,642

Restructuring costs

4,042

(882)

5,578

(882)

Asset impairment

1,658

1,850

2,465

1,850

Loss from operations

(29,489)

(81,416)

(61,509)

(104,586)

Transaction costs

(173)

7,938

(2,213)

1,457

Finance costs, net

(2,458)

(26,505)

(7,631)

(26,444)

Change in estimate of fair value of derivative warrants

2,240

23,656

7,042

15,356

Foreign exchange gain (loss)

(31)

161

(194)

11

Gain (loss) on disposition of assets

(77)

402

(261)

402

Loss before income tax

(29,988)

(75,764)

(64,766)

(113,804)

Income tax recovery

1,791

1,791

Net loss from continuing operations

(29,988)

(73,973)

(64,766)

(112,013)

Net loss from discontinued operations

(3,170)

(4,535)

Net loss

(33,158)

(73,973)

(69,301)

(112,013)

Equity-accounted investees – share of other
comprehensive income (loss)

(11,621)

12,727

(12,006)

5,994

Gain on translation of foreign operations

(5)

Comprehensive loss

(44,784)

(61,246)

(81,307)

(106,019)

Net loss from continuing operations attributable to:

Owners of the Company

(29,350)

(73,301)

(63,553)

(111,205)

Non-controlling interest

(638)

(672)

(1,213)

(808)

(29,988)

(73,973)

(64,766)

(112,013)

Net income (loss) attributable to:

Owners of the Company

(32,520)

(73,301)

(68,088)

(111,205)

Non-controlling interest

(638)

(672)

(1,213)

(808)

(33,158)

(73,973)

(69,301)

(112,013)

Comprehensive income (loss) attributable to:

Owners of the Company

(44,146)

(60,574)

(80,094)

(105,211)

Non-controlling interest

(638)

(672)

(1,213)

(808)

(44,784)

(61,246)

(81,307)

(106,019)

Condensed Consolidated Interim Statement of Financial Position
(Unaudited – expressed in thousands of Canadian dollars)

As at

June 30, 2023

December 31, 2022

Assets

Current assets

Cash and cash equivalents

185,455

279,586

Restricted cash

19,456

19,338

Marketable securities

3,535

21,926

Accounts receivable

32,661

22,636

Biological assets

1,330

3,477

Inventory

160,407

127,782

Prepaid expenses and deposits

21,792

10,110

Investments

23,038

6,552

Assets held for sale

8,391

6,375

Net investment in subleases

3,656

3,701

459,721

501,483

Non-current assets

Long-term deposits

9,766

8,584

Right of use assets

136,947

134,154

Property, plant and equipment

181,841

143,409

Net investment in subleases

18,918

19,618

Intangible assets

74,446

74,885

Investments

9,638

90,702

Equity-accounted investees

532,818

519,255

Goodwill

147,680

67,260

Total assets

1,571,775

1,559,350

Liabilities

Current liabilities

Accounts payable and accrued liabilities

62,557

48,153

Lease liabilities

35,982

30,206

Derivative warrants

3,960

11,002

102,499

89,361

Non-current liabilities

Lease liabilities

136,136

139,625

Other liabilities

5,252

2,709

Total liabilities

243,887

231,695

Shareholders’ equity

Share capital

2,365,845

2,292,810

Warrants

2,260

2,260

Contributed surplus

73,636

68,961

Contingent consideration

2,279

2,279

Accumulated deficit

(1,156,279)

(1,091,999)

Accumulated other comprehensive income

20,182

32,188

Total shareholders’ equity

1,307,923

1,306,499

Non-controlling interest

19,965

21,156

Total liabilities and shareholders’ equity

1,571,775

1,559,350

Condensed Consolidated Interim Statement of Cash Flows
(Unaudited – expressed in thousands of Canadian dollars)

Three months ended
June 30

Six months ended
June 30

2023

2022

2023

2022

Cash provided by (used in):

Operating activities

Net loss for the period

(33,158)

(73,973)

(69,301)

(112,013)

Adjustments for:

Income tax recovery

(1,791)

(1,791)

Interest and fee revenue

(3,421)

(2,577)

(7,632)

(6,438)

Change in fair value of biological assets

1,413

388

4,948

(3,302)

Share-based compensation

3,893

438

6,102

4,642

Depreciation and amortization

14,674

10,538

32,933

12,977

Loss (gain) on disposition of assets

77

(402)

261

(402)

Inventory obsolescence

4,291

3,871

13,468

5,852

Finance costs

2,458

26,505

7,631

26,444

Change in estimate of fair value of derivative warrants

(2,240)

(23,656)

(7,042)

(15,356)

Unrealized foreign exchange loss (gain)

(72)

19

(24)

35

Asset impairment

1,658

1,850

2,465

1,850

Share of (profit) loss of equity-accounted investees

936

37,978

(8,580)

33,887

Loss on settlement of marketable securities

48,988

92,792

Unrealized (gain) loss on marketable securities

(44,968)

35,338

(83,603)

53,172

Additions to marketable securities

(2,899)

(3,500)

Proceeds from settlement of marketable securities

3,437

3,463

Income distributions from equity-accounted investees

685

Interest received

3,217

2,084

6,920

5,799

Change in non-cash working capital

(14,193)

(31,584)

(56,755)

(46,434)

Net cash used in operating activities from continuing operations

(13,010)

(17,873)

(61,954)

(43,893)

Net cash provided by operating activities from discontinued operations

4,167

4,314

Net cash used in operating activities

(8,843)

(17,873)

(57,640)

(43,893)

Investing activities

Additions to property, plant and equipment

(1,247)

(3,554)

(2,641)

(4,535)

Additions to intangible assets

(39)

1

(56)

(55)

Additions to investments

125

337

(702)

(14,094)

Additions to equity-accounted investees

(9,443)

(36,880)

(16,989)

(94,200)

Proceeds from disposal of property, plant and equipment

55

4,000

137

4,000

Acquisitions, net of cash acquired

3,695

(31,149)

Change in non-cash working capital

1,586

294

1,127

259

Net cash used in investing activities from continuing operations

(8,963)

(35,802)

(15,429)

(139,774)

Net cash used in investing activities from discontinued operations

Net cash used in investing activities

(8,963)

(35,802)

(15,429)

(139,774)

Financing activities

Change in restricted cash

(76)

2,541

(118)

7,607

Payments on lease liabilities, net

(10,116)

(9,177)

(19,607)

(9,624)

Repurchase of common shares, net of costs

(2,053)

(1,536)

(2,053)

Repayment of long-term debt

(10,000)

Change in non-cash working capital

200

2,170

199

2,116

Net cash used in financing activities from continuing operations

(9,992)

(6,519)

(21,062)

(11,954)

Net cash used in financing activities from discontinued operations

Net cash used in financing activities

(9,992)

(6,519)

(21,062)

(11,954)

Change in cash and cash equivalents

(27,798)

(60,194)

(94,131)

(195,621)

Cash and cash equivalents, beginning of period

213,253

422,824

279,586

558,251

Cash and cash equivalents, end of period

185,455

362,630

185,455

362,630

SPECIFIED FINANCIAL MEASURES

Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company’s operating results in the same manner as the management team.

ADJUSTED EBITDA

Adjusted EBITDA is a non-IFRS measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results in a manner similar to its management team. Adjusted EBITDA is defined as net income (loss) from continuing operations before finance costs, depreciation and amortization, accretion expense, income tax recovery and excluding changes in fair value of biological assets, changes in fair value realized through inventory, unrealized foreign exchange gains or losses, unrealized gains or losses on marketable securities, changes in fair value of derivative warrants, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment, cost of sales non-cash component, inventory impairment (recovery) and obsolescence, restructuring costs and transaction costs. The Company presents both consolidated or total Adjusted EBITDA and Adjusted EBITDA by operating segment.

OPERATING SEGMENTS

($000s)

Liquor
Retail

Cannabis
Retail

Cannabis
Operations

Investments

Corporate

Total

Three months ended June 30, 2023

Net earnings (loss)

6,714

1,221

(13,831)

(1,917)

(22,175)

(29,988)

Adjustments

Finance costs

1,490

1,111

(400)

257

2,458

Change in estimate of fair value of
derivative warrants

(2,240)

(2,240)

Depreciation and amortization

8,161

3,361

650

1,271

13,443

Change in fair value of biological assets

1,413

1,413

Change in fair value realized through
inventory

(2,048)

(2,048)

Unrealized foreign exchange (gain) loss

(2)

(70)

(72)

Unrealized (gain) loss on marketable
securities

214

(45,182)

(44,968)

Realized loss on marketable securities

49,093

49,093

Share-based compensation

15

3,878

3,893

Asset impairment

458

1,200

1,658

Loss (gain) on disposition of PP&E

5

72

77

Cost of sales non-cash component (1)

969

969

Inventory impairment (recovery) and
obsolescence

4,291

4,291

Restructuring costs

1,282

2,760

4,042

Transaction costs

173

173

Adjusted EBITDA

16,363

6,171

(6,258)

2,251

(16,333)

2,194

 (1) Cost of sales non-cash component is comprised of depreciation expense

OPERATING SEGMENTS

($000s)

Liquor
Retail

Cannabis
Retail

Cannabis
Operations

Investments

Corporate

Total

Three months ended June 30, 2022

Net earnings (loss)

8,379

447

(8,036)

(90,487)

15,724

(73,973)

Adjustments

Finance costs

2,874

1,070

195

22,305

61

26,505

Change in estimate of fair value of
derivative warrants

(56)

(23,600)

(23,656)

Depreciation and amortization

5,315

3,370

115

8,800

Income tax recovery

(1,791)

(1,791)

Change in fair value of biological assets

388

388

Change in fair value realized through
inventory

2,066

2,066

Unrealized foreign exchange (gain) loss

9

10

19

Unrealized (gain) loss on marketable
securities

35,338

35,338

Share-based compensation

(180)

618

438

Asset impairment

1,850

1,850

Loss (gain) on disposition of PP&E

35

15

(452)

(402)

Cost of sales non-cash component (1)

3,440

3,440

Inventory impairment (recovery) and
obsolescence

3,871

3,871

Restructuring costs

(882)

(882)

Transaction costs

(7,938)

(7,938)

Adjusted EBITDA

16,612

4,666

3,332

(35,517)

(15,020)

(25,927)

(1) Cost of sales non-cash component is comprised of depreciation expense

SOURCE Sundial Growers Inc.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Technical420 newsletter.

 All good -- no spamming here.